From Hit to IND: Streamlining Drug Discovery Through Multidisciplinary Integration


Drug discovery is inherently a time-consuming and costly endeavor. How can today’s new drug innovators accelerate their programs through a simple, fast, and streamlined process—especially when working with multiple vendors? Should they rely on a single partner for end-to-end support, or engage specialized vendors for different workstreams such as chemistry, biology, and DMPK?

From the innovator’s perspective, Integrated Drug Discovery (IDD) is an emerging paradigm that, while offering many advantages, also presents unique challenges. This webinar will explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies (AI and Machine Learning), and regulatory compliance.

From the CRO’s perspective, we will share two real-world case studies illustrating how our problem-solving approach helps clients navigate the drug discovery journey — from hit/lead identification to PCC/IND-enabling milestones. We will highlight the common challenges encountered and discuss the critical factors that contribute to successful outcomes and potentially fast-track programs to the clinic.

What You Will Learn

  • How to manage multidisciplinary integration at the stage of discovery
  • Key factors, challenges, and solutions for accelerating molecules to clinical stage
  • Real-world case studies



Source link

Scroll to Top